Open AccessResponse to Second Generation Antipsychotics in Youth with Comorbid Bipolar Disorder and Autism Spectrum Disorder
Author(s) -
Joshi Gagan,
Biederman Joseph,
Wozniak Janet,
Doyle Robert,
Hammerness Paul,
Galdo Maribel,
Sullivan Nora,
Williams Courtney,
Brethel Kristin,
Woodworth K. Yvonne,
Mick Eric
Publication year - 2012
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/j.1755-5949.2010.00219.x
Subject(s) - aripiprazole , ziprasidone , quetiapine , autism spectrum disorder , comorbidity , olanzapine , risperidone , bipolar disorder , bipolar i disorder , psychiatry , psychology , tolerability , autism , clinical psychology , medicine , schizophrenia (object oriented programming) , mania , mood , adverse effect
SUMMARY Objective: To assess the impact of comorbid autism spectrum disorders (ASD) on the response to second‐generation antipsychotics (SGA) in pediatric bipolar disorder (BPD). Methods: Secondary analysis of identically designed 8‐week open‐label trials of SGA monotherapy (risperidone, olanzapine, quetiapine, ziprasidone, or aripiprazole) in youth with BPD. Results: Of the 151 BPD subjects 15% ( n = 23) met criteria for comorbid ASD. There were no differences in the rate of antimanic response (YMRS change ≥30% or CGI‐Improvement ≤2: 65% vs. 69%; P = 0.7) in the presence of comorbid ASD. Conclusion: No difference observed in the rate of antimanic response or tolerability to SGA monotherapy in the presence of ASD comorbidity.